Business Wire

MA-ELECTRA-VEHICLES

11.4.2022 08:02:11 CEST | Business Wire | Press release

Share
Electra Vehicles, Inc. Welcomes Electric Vehicle Industry Expert Alexander Hitzinger to Board of Directors

On April 5, 2022, automotive industry leader Alexander (Alex) Hitzinger was appointed to the Board of Directors at Electra Vehicles, Inc. as an Independent Board Member. The appointment marks another critical milestone for the growing AI battery software startup as the company expands its expert roster of electric vehicle leaders from the transportation industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220410005015/en/

Hitzinger boasts an extensive engineering and leadership career where he led key autonomous and electric vehicle projects. His career began at Toyota as a development engineer before working in the Formula 1 world as Head of Formula 1 Development at Cosworth and Head of Advanced Technologies at Red Bull’s Formula 1 Team. His penchant for leading cutting edge automotive technology projects led him to serve as Technical Director for the three times victorious Porsche 919 at the 24 Hours of Le Mans and Head of Product Design at Apple for Project Titan before co-founding and serving as CEO at ARTEMIS, where he lead the creation of a visionary autonomous vehicle concept. Most recently, Hitzinger served as Senior Vice President of Autonomous Driving at VW Group and Member of the Executive Board VWN, where he was involved in the development of the ID Buzz. With more than 20 years of experience in the automotive and electric vehicle industries, Hitzinger begins a new phase of his career with the aim of supporting promising young companies with disruptive technologies as they enter the automotive and electric vehicle world stage.

“I am looking for outstanding companies, with industry leading technologies, where I can help the management in deriving a successful strategy for scaling the company and the technology. Electra Vehicles, Inc. is exactly this type of company,” says Hitzinger. “The electrification of transportation is in full swing, but in many areas of the technology stack, there are still outdated technologies deployed. Electra is closing one of these gaps with its sophisticated battery performance management, and therefore I couldn’t be happier about joining Electra’s Board of Directors.”

CEO and Co-founder of Electra Vehicles, Fabrizio Martini, expresses his delight at welcoming Hitzinger to the Board: “The Electra team is honored, proud, and glad to welcome on its Board of Directors an extraordinary visionary like Alex Hitzinger. Alex is a world-renowned expert and award-winning talent in the Mobility sector. His experience, knowledge, and vision will guide Electra Vehicles, Inc. to make a significant global impact. I am genuinely excited to start partnering with Alex to bring the most advanced ML/AI-based technology worldwide for battery management solutions in the marketplace to enhance today’s transition to electric transportation.”

About Electra Vehicles, Inc.

Electra Vehicles is a leading B2B AI software company headquartered in Boston, MA, USA with a presence in Italy that produces embedded and Cloud-connected software to optimize the performance of electric vehicle battery systems for range, lifetime, charging, and safety benefits. Electra’s onboard EVE-Ai™ 360 Adaptive Controls and Cloud-based EVE-Ai™ Fleet Analytics are software that provide battery system performance insights, battery-conscious driver recommendations, and intelligent charging control strategies based on a continuously updating Adaptive Cell Model, making Electra’s EVE-Ai™ a necessity for electrified applications worldwide. In 2021, Electra Vehicles, Inc. became a BlackBerry IVY Fund investee and is a proud member of the BlackBerry IVY ecosystem.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye